sepsi
defin
lifethreaten
organ
dysfunct
caus
dysregul
host
respons
infect
even
modest
degre
organ
dysfunct
may
lead
deterior
septic
patient
overal
mortal
approxim
thu
earli
recognit
merit
prompt
appropri
intervent
acut
kidney
injuri
aki
common
critic
ill
patient
potenti
lifethreaten
factor
associ
signific
morbid
mortal
sepsi
common
precipit
factor
develop
aki
sepsisassoci
aki
saaki
often
acut
sever
compar
aki
without
sepsi
pose
signific
clinic
challeng
decreas
urin
output
increas
serum
creatinin
cr
use
surrog
marker
decreas
glomerular
filtrat
rate
gfr
defin
aki
howev
limit
classic
paramet
assess
acut
kidney
attack
damag
new
renal
biomark
explor
neutrophil
gelatinaseassoci
lipocalin
ngal
identifi
good
predictor
aki
well
effici
test
predict
clinic
outcom
critic
ill
patient
sever
equat
isotop
dilut
mass
spectrometri
idm
traceablemodif
diet
renal
diseas
mdrd
studi
equat
chronic
kidney
diseas
epidemiolog
collabor
ckdepi
equat
use
serum
cr
serum
cystatin
c
cysc
demograph
variabl
use
estim
gfr
howev
equat
estim
gfr
egfr
develop
stabl
patient
chronic
renal
insuffici
valid
critic
ill
patient
enkephalin
encod
proenkephalin
gene
penk
chromosom
endogen
opioid
involv
variou
physiolog
process
influenc
kidney
function
proenkephalin
penk
amino
acid
proenkephalin
stabl
surrog
marker
endogen
enkephalin
suggest
novel
biomark
aki
periop
critic
set
studi
investig
clinic
util
penk
comparison
ngal
term
aki
detect
prognosi
predict
septic
patient
addit
compar
level
two
kidney
biomark
use
four
differ
egfr
equat
mdrd
studi
three
ckdepi
equat
explor
equat
vari
across
aki
sepsi
sever
comparison
highlight
necess
stabil
biomark
contrast
unreli
egfr
critic
ill
patient
total
patient
clinic
suspicion
sepsi
decemb
june
patient
diagnos
sepsi
accord
diagnost
criteria
surviv
sepsi
campaign
except
patient
without
avail
sampl
total
patient
enrol
studi
definit
sepsi
septic
shock
revis
earli
enrol
patient
recategor
accord
new
definit
patient
diagnos
sepsi
patient
septic
shock
patient
could
includ
sepsi
group
accord
new
definit
arbitrarili
group
suspect
sepsi
sampl
size
thought
approxim
power
detect
differ
independ
variabl
three
sepsi
grade
group
twosid
signific
level
patient
medic
record
review
clinic
demograph
data
basic
characterist
present
tabl
presenc
aki
defin
use
kidney
diseas
improv
global
outcom
kdigo
diagnost
criteria
penk
ngal
serum
cr
cysc
concentr
measur
time
patient
enrol
serum
cr
delta
valu
assess
basi
concentr
hr
post
enrol
aki
diagnosi
studi
perform
accord
declar
helsinki
studi
protocol
review
approv
exempt
institut
review
board
konkuk
univers
medic
center
seoul
korea
medic
record
review
without
identifi
inform
studi
requir
addit
blood
sampl
intervent
biomark
measur
use
remnant
blood
sampl
would
discard
follow
routin
use
patient
avail
edta
plasma
serum
sampl
collect
day
sepsi
diagnosi
divid
small
aliquot
avoid
repeat
freez
thaw
immedi
store
use
frozen
sampl
thaw
room
temperatur
gentli
mix
prior
biomark
measur
plasma
penk
measur
use
sphingotest
penkid
assay
sphingotec
gmbh
hennigsdorf
germani
immunoassay
monoclon
antibodi
specif
penk
peptid
amino
acid
penk
standard
penk
peptid
sampl
incub
tube
detector
antibodi
tube
wash
bound
chemiluminesc
detect
luminomet
berthold
bad
wildbad
germani
lower
limit
detect
pmoll
measur
rang
pmoll
mean
withinlaboratori
imprecis
studi
period
percentil
normal
distribut
pmoll
recent
describ
diet
cancer
studi
consid
refer
limit
plasma
ngal
measur
use
triag
ngal
assay
aler
inc
san
diego
ca
usa
accord
manufactur
instruct
briefli
sever
drop
edta
plasma
sampl
ad
sampl
port
devic
sampl
react
fluoresc
antibodi
conjug
complex
captur
discret
zone
specif
ngal
devic
display
concentr
plasma
ngal
approxim
min
later
measur
rang
ngml
mean
withinlaboratori
imprecis
studi
period
medic
decis
point
plasma
ngal
set
ngml
serum
cr
measur
use
toshiba
analyz
toshiba
medic
system
tokyo
japan
roch
calibr
reagent
roch
diagnost
indianapoli
usa
traceabl
idm
refer
method
dynam
measur
rang
mgdl
mean
withinlaboratori
imprecis
studi
period
cysc
determin
roch
coba
modular
system
use
roch
tinaqu
cystatin
c
gen
particl
enhanc
immunonephelometr
assay
measur
rang
mgl
mean
withinlaboratori
imprecis
studi
period
egfr
calcul
use
mdrd
studi
equat
ckdepi
equat
use
cr
cysc
crcysc
variabl
demograph
variabl
assess
egfr
rather
use
arbitrari
categori
adopt
six
egfr
categori
accord
kdigo
guidelin
gfr
consid
normal
data
check
normal
distribut
use
shapirowilk
test
express
median
interquartil
rang
number
percentag
group
compar
use
mannwhitney
u
test
kruskalw
test
posthoc
multipl
comparison
roc
curv
area
curv
auc
use
illustr
variou
cutoff
level
sensit
specif
auc
report
confid
interv
ci
assess
follow
fail
poor
fair
good
excel
nest
logist
regress
model
roc
curv
use
compar
variabl
predict
aki
renal
replac
therapi
rrt
agreement
categor
group
assess
use
interrat
agreement
statist
kappa
valu
absenc
agreement
none
slight
fair
moder
substanti
almost
perfect
agreement
kaplanmei
surviv
curv
use
analyz
prognost
valu
biomark
egfr
mortal
compar
favor
unfavor
group
use
hazard
ratio
hr
ci
spss
softwar
version
spss
inc
chicago
il
usa
medcalc
softwar
version
medcalc
softwar
mariakerk
belgium
use
statist
analys
p
valu
consid
statist
signific
tabl
show
comparison
penk
ngal
egfr
accord
sepsi
sever
penk
ngal
concentr
differ
significantli
accord
sepsi
sever
p
respect
egfr
base
mdrd
studi
three
ckdepi
equat
decreas
significantli
accord
sepsi
sever
p
aki
occur
patient
suspectedsepsi
patient
sepsi
patient
septic
shock
tabl
penk
ngal
biomark
four
egfr
equat
differ
significantli
patient
without
aki
stage
sepsi
note
sepsi
stage
penk
concentr
increas
without
aki
ngal
concentr
increas
substanti
compar
clinic
cutoff
valu
even
without
aki
pmoll
vs
ngml
egfr
equat
ckdepicr
ckdepicrcysc
indic
normal
kidney
function
septic
patient
without
aki
roc
curv
compar
aki
diagnosi
patient
fig
penk
auc
four
egfr
equat
auc
respect
show
fair
discriminatori
abil
ngal
demonstr
poor
discriminatori
abil
auc
howev
penk
ngal
four
egfr
equat
compar
show
statist
differ
refin
analysi
base
nest
logist
regress
model
show
penk
superior
ngal
p
inferior
egfr
equat
base
mdrd
cr
crcysc
p
penk
exhibit
statist
superior
egfr
base
cysc
ngal
inferior
egfr
equat
p
optim
cutoff
valu
aki
diagnosi
pmoll
penk
ngml
ngal
rang
egfr
equat
regard
rrt
penk
ngal
concentr
significantli
higher
patient
rrt
patient
without
rrt
penk
vs
pmoll
p
ngal
vs
ngml
base
roc
curv
analysi
penk
show
good
perform
ngal
show
fair
perform
predict
rrt
auc
vs
distribut
gfr
categori
vari
across
egfr
equat
fig
proport
reduc
gfr
highest
base
ckdepicysc
equat
lowest
base
ckdepicr
equat
show
signific
differ
vs
p
chisquar
test
note
pair
egfr
equat
show
minim
weak
agreement
defin
reduc
gfr
distribut
penk
ngal
concentr
differ
significantli
accord
gfr
categori
p
fig
penk
ngal
concentr
increas
significantli
accord
gfr
categori
base
mdrd
studi
ckdepi
equat
p
normal
gfr
categori
penk
concentr
pmoll
cutoff
obtain
roc
curv
analysi
also
lower
similar
percentil
normal
rang
pmoll
ngal
concentr
also
ngml
cutoff
obtain
roc
curv
analysi
howev
higher
literatur
manufacturerrecommend
ngml
cutoff
term
mortal
except
ngal
penk
concentr
egfr
show
signific
differ
survivor
nonsurvivor
base
four
equat
p
tabl
base
surviv
analysi
use
two
differ
cutoff
optim
roc
curv
analysi
cutoff
literatur
andor
manufacturerrecommend
cutoff
penk
egfr
equat
show
signific
differ
two
group
favor
vs
unfavor
howev
signific
differ
observ
ngal
regardless
cutoff
penk
show
highest
hr
pmoll
cutoff
valu
p
studi
penk
concentr
ngal
concentr
egfr
show
signific
differ
accord
sepsi
sever
tabl
penk
ngal
concentr
increas
significantli
egfr
decreas
significantli
accord
sepsi
sever
base
roc
curv
analysi
penk
four
egfr
equat
show
fair
discriminatori
abil
ngal
show
poor
perform
aki
diagnosi
fig
nest
logist
regress
model
penk
superior
ngal
inferior
egfr
equat
base
mdrd
studi
cr
crcysc
p
penk
display
statist
superior
egfr
base
cysc
ngal
inferior
egfr
equat
p
note
penk
ngal
concentr
significantli
differ
two
group
rrt
penk
predict
rrt
better
ngal
result
indic
perform
test
aki
biomark
distinctli
better
egfr
howev
penk
might
predict
need
rrt
accur
accord
data
pair
four
egfr
equat
show
minim
weak
agreement
defin
reduc
gfr
egfr
fig
proport
reduc
gfr
highest
base
ckdepicysc
equat
lowest
base
ckdepicr
equat
vs
p
find
impli
clinic
decis
regard
reduc
gfr
greatli
affect
egfr
equat
use
line
current
recommend
use
formula
estim
gfr
critic
ill
patient
although
recommend
estim
gfr
calcul
cr
clearanc
use
uvp
mlmin
formula
patient
techniqu
requir
collect
least
one
hour
worth
urin
could
constitut
obstacl
practic
viewpoint
current
serum
crbase
aki
definit
aki
mortal
morbid
remain
high
detect
suboptim
andor
earli
kidney
injuri
optim
thu
aki
diagnosi
shift
clinic
molecular
diagnosi
regard
avail
stabl
surrog
renal
biomark
would
benefici
penk
could
promis
option
instead
use
equat
formula
anoth
notic
find
penk
ngal
four
egfr
equat
show
signific
differ
patient
without
aki
sepsi
stage
tabl
moreov
sepsi
stage
penk
concentr
increas
without
aki
ngal
concentr
increas
substanti
clinic
cutoff
valu
even
without
aki
pmoll
penk
vs
ngml
ngal
four
egfr
equat
ckdepicr
ckdepicrcysc
indic
normal
kidney
function
septic
patient
without
aki
pathophysiolog
drive
saaki
complet
understood
distinct
aki
saaki
may
numer
driver
includ
ischemicreperfus
injuri
glomerulu
inflamm
specif
part
nephron
hypox
andor
oxid
stress
cytokin
chemokin
driven
tubular
injuri
tubular
mesenchym
apoptosi
moreov
septic
shock
subset
sepsi
character
state
acut
circulatori
failur
associ
infect
data
show
renal
biomark
increas
four
egfr
equat
decreas
septic
shock
stage
even
patient
without
aki
tabl
tabl
addit
role
renal
biomark
penk
also
report
independ
predictor
heart
failur
taken
togeth
increas
penk
concentr
septic
shock
stage
explain
renal
cardiac
dysfunct
observ
decreas
egfr
septic
shock
without
aki
also
support
recent
recommend
use
egfr
equat
critic
ill
patient
studi
aki
diagnos
base
serum
cr
chang
accord
kdigo
criteria
howev
increas
serum
cr
occur
rel
late
hr
kidney
injuri
view
inher
limit
serum
crbase
definit
aki
subclin
aki
suggest
acut
dialysi
qualiti
initi
adqi
consensu
work
group
high
penk
concentr
septic
shock
stage
may
suggest
presenc
subclin
aki
detect
current
definit
penk
ngal
concentr
increas
significantli
gfr
reduc
accord
gfr
categori
fig
note
regardless
egfr
equat
use
penk
concentr
constantli
lower
pmoll
cutoff
normal
gfr
categori
also
lower
percentil
normal
rang
pmoll
howev
ngal
concentr
higher
literatur
manufacturerrecommend
ngml
cutoff
although
ngml
roc
curv
analysi
cutoff
find
impli
penk
may
reflect
gfr
better
ngal
may
influenc
inflamm
otto
et
al
report
function
circul
plasma
ngal
restrict
sole
detect
aki
might
involv
immun
respons
inflamm
penk
would
reliabl
object
altern
egfr
equat
defin
reduc
gfr
presenc
aki
septic
patient
marino
et
al
report
admiss
penk
ngal
concentr
increas
patient
die
within
seven
day
admiss
procalcitonin
cr
clearanc
present
studi
penk
concentr
egfr
base
four
equat
show
signific
differ
survivor
nonsurvivor
tabl
also
observ
signific
differ
two
group
favor
vs
unfavor
surviv
analysi
use
two
differ
cutoff
howev
signific
differ
observ
ngal
regardless
cutoff
data
suggest
penk
superior
ngal
predict
clinic
outcom
septic
patient
moreov
highest
hr
observ
pmoll
cutoff
appli
penk
find
support
appropri
clinic
use
cutoff
septic
condit
studi
sever
limit
focus
comparison
penk
ngal
concentr
egfr
equat
term
aki
diagnosi
prognosi
predict
thu
investig
distribut
biomark
relat
specif
bacteriolog
identif
addit
compar
penk
ngal
aki
biomark
includ
interleukin
kidney
injuri
could
collect
followup
sampl
serial
observ
biomark
septic
patient
studi
crosssect
retrospect
registri
studi
therefor
difficult
observ
temporari
develop
aki
associ
penk
ngal
increas
although
compar
egfr
accord
mdrd
studi
ckdepi
equat
measur
actual
valu
gfr
therefor
could
determin
egfr
valu
closest
true
gfr
lastli
inform
regard
penk
dynam
pre
postrrt
low
molecular
weight
kda
might
dialyz
thu
studi
necessari
answer
question
conclus
first
studi
demonstr
use
penk
comparison
ngal
egfr
equat
diagnosi
aki
predict
prognosi
septic
patient
regardless
variabl
gfr
categori
differ
egfr
equat
penk
show
constant
signific
associ
egfr
equat
contrast
ngal
penk
influenc
inflamm
predict
clinic
outcom
diagnost
robust
predict
power
surviv
penk
constitut
promis
biomark
critic
care
set
includ
sepsi
